Achilles Therapeutics Discontinued Its TIL-Based cNeT Program And Closed Phase 1/2A CHIRON and THETIS Trials, And It Will Refocus Its Strategy To Explore Further Engagement With Third Parties, The Company Has Engaged BofA Securities To Provide Strategic Financial Advice
Author: Benzinga Newsdesk | September 19, 2024 06:12am